Biopharm Co. Seelos Files For Ch. 11 After Nasdaq Delisting

By Hilary Russ · November 18, 2024, 5:38 PM EST

Publicly traded biopharmaceutical company Seelos Therapeutics Inc. sought Chapter 11 protection in New York on Saturday, citing between $10 million and $50 million in estimated liabilities....

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Petition

Case Information

Case Title

SEELOS THERAPEUTICS, INC.

Case Number

Court

New York Southern

Nature of Suit

Date Filed

November 16, 2024

Recent Articles By Hilary

December 18, 2024
Meet The Attorneys Helping Hearthside Through Ch. 11
December 11, 2024
Q&A With 1MDB Co-Liquidator Angela Barkhouse
December 10, 2024
US Trustee Seeks Oversight Of Hospital Chain's Ch. 11
December 06, 2024
FTX Says Three Arrows Can't Add $1.5B To Ch. 11 Claims
December 05, 2024
Meet The Attorneys Directing Film Finances' Ch. 11 Case
November 26, 2024
Purdue Wins Shortened Extension Of Ch. 11 Deal Talks
November 25, 2024
Madoff Trustee Inks Deal To End $21M Clawback Against ZCM
November 22, 2024
Snack Maker Hearthside Files For Ch. 11 To Shed $1.9B Debt
November 20, 2024
Lawyers In Purdue Bankruptcy Get OK For Millions In Fees
November 14, 2024
Maryland Seeks To Undo Litigation Pause In Purdue Appeal